BioCentury | Apr 1, 2020
Distillery Therapeutics

Two glycopeptides for drug-resistant Gram-positive infections

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus; Gram-positive bacterial infections The glycopeptides corbomycin and complestatin could treat methicillin- and daptomycin-resistant S. aureus and other Gram-positive infections by interfering with cell wall remodeling. Complestatin and related compounds...
BC Innovations | Sep 19, 2019
Targets & Mechanisms

Regeneron's new take on bispecifics: activating complement

Regeneron's new bispecific antibodies for the first time tap the complement system -- going beyond the immune cells traditionally targeted, and expanding the modality into new patient populations and indications. With proof of concept studies...
BC Innovations | Aug 14, 2019
Distillery Therapeutics

Antihelminthic compound bithionol could treat MRSA infection

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus The antihelminthic bithionol could be repurposed to treat methicillin-resistant S. aureus (MRSA) infections. In bacterial growth assays, bithionol reduced growth of three MRSA strains and a vancomycin-resistant S. aureus...
BC Innovations | Jun 28, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture studies identified three cadmium-based supramolecule coordination complexes (SCCs) that could help treat methicillin-resistant Staphylococcus aureus (MRSA) infection. The three SCCs consist of hexagonal-shaped rings that incorporate 12, 18 or 24 cadmium...
BC Innovations | May 25, 2018
Product R&D

Peptides step up

New screening platforms and synthetic approaches could finally solve some of the longstanding hurdles to turning antimicrobial peptides into therapeutic candidates to combat antibacterial resistance, overcoming their history of limited clinical efficacy, systemic toxicity and...
BC Week In Review | Dec 1, 2017
Clinical News

CHMP recommends pediatric label expansion for Merck's Cubicin

EMA's CHMP recommended approval of a label expansion for Cubicin daptomycin (MK-3009) from Merck & Co. Inc. (NYSE:MRK) to include patients ages 1-17 with Staphylococcus aureus bacteremia associated with complicated skin or soft-tissue infections (cSSTI)....
BC Innovations | Feb 22, 2017
Distillery Techniques

Chemistry

TECHNOLOGY: Synthetic chemistry A method of using bacterial enzymes to add prenyl groups to aryl-containing scaffolds could enable the discovery of novel bioactive molecules. The single-step chemical reaction involved utilizing C-prenyltransferases derived from a Streptomyces...
BC Week In Review | Nov 16, 2015
Company News

Merck, Pfizer infectious news

The U.S. Court of Appeals for the Federal Circuit upheld a district court decision that Merck’s antibiotic Cubicin daptomycin has patent exclusivity until June 15, 2016. CAFC upheld the validity of one Orange Book patent,...
BC Extra | Nov 14, 2015
Company News

CAFC decision would allow Cubicin generics in 2016

The U.S. Court of Appeals for the Federal Circuit upheld a district court decision to invalidate four patents covering Cubicin daptomycin from Merck & Co. Inc. (NYSE:MRK). The decision would allow generic competitors to enter...
BC Week In Review | Nov 9, 2015
Clinical News

Cubicin daptomycin regulatory update

EMA’s CHMP recommended approval of a label expansion for Cubicin daptomycin from Novartis to include patients ages 1-17 with complicated skin and soft-tissue infections (cSSTIs). The cyclic lipopeptide antibiotic is approved in the EU to...
Items per page:
1 - 10 of 368